
IPA
Immunoprecise Antibodies Ltd
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.410
Open
2.375
VWAP
2.17
Vol
2.02M
Mkt Cap
98.85M
Low
2.000
Amount
4.37M
EV/EBITDA(TTM)
--
Total Shares
26.32M
EV
98.86M
EV/OCF(TTM)
--
P/S(TTM)
3.75
ImmunoPrecise Antibodies Ltd. is a biotherapeutic research company. It is advancing Bio-Native AI at the intersection of biology and computation. Its LENSai and HYFT platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. The core of its operations encompasses a diverse suite of proprietary technologies that aid in the exploration, discovery, and development of novel drugs and biologics. Integrated within its wet lab infrastructure is a diverse array of in silico technologies. As an end-to-end service provider of antibody discovery and development, its computational methodologies allow the Company to perform detailed and comprehensive evaluations across various stages of biologic discovery and development. It is involved in antibody characterization studies, which encompass affinity measurements, epitope landscape profiling, and others.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
7.20M
+17.55%
--
--
6.40M
+21.6%
--
--
7.89M
+22.16%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for ImmunoPrecise Antibodies Ltd. (IPA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 368.55%.
Revenue Estimates for FY2025
No Change

0.00%
In Past 3 Month
Stock Price
Go Up

+368.55%
In Past 3 Month
1 Analyst Rating

131.48% Upside
Wall Street analysts forecast IPA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IPA is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy

131.48% Upside
Current: 2.160

Low
5.00
Averages
5.00
High
5.00

131.48% Upside
Current: 2.160

Low
5.00
Averages
5.00
High
5.00
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$5
2025-04-11
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$5
2025-04-11
Reiterates
Strong Buy
Reason
Benchmark
Robert Wasserman
Buy
Reiterates
$3
2025-04-01
Reason
Benchmark
Robert Wasserman
Price Target
$3
2025-04-01
Reiterates
Buy
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Maintains
$7 → $5
2025-03-31
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$7 → $5
2025-03-31
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$7
2025-03-14
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$7
2025-03-14
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Maintains
$9 → $7
2024-12-11
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$9 → $7
2024-12-11
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$9
2024-09-17
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$9
2024-09-17
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Immunoprecise Antibodies Ltd (IPA.O) is -19.29, compared to its 5-year average forward P/E of -2.16. For a more detailed relative valuation and DCF analysis to assess Immunoprecise Antibodies Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-2.16
Current PE
-19.29
Overvalued PE
0.98
Undervalued PE
-5.30
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-3.04
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
18.69
Undervalued EV/EBITDA
-24.76
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
5.12
Current PS
5.01
Overvalued PS
8.61
Undervalued PS
1.64
Financials
Annual
Quarterly
FY2025Q3
YoY :
-1.13%
6.15M
Total Revenue
FY2025Q3
YoY :
-1.53%
-3.29M
Operating Profit
FY2025Q3
YoY :
+703.32%
-21.52M
Net Income after Tax
FY2025Q3
YoY :
+560.00%
-0.66
EPS - Diluted
FY2025Q3
-1.32M
Free Cash Flow
FY2025Q3
YoY :
+8.63%
43.44
Gross Profit Margin - %
FY2025Q3
YoY :
+104.77%
-39.50
FCF Margin - %
FY2025Q3
YoY :
+712.54%
-349.88
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
IPA News & Events
Events Timeline
2025-07-24 (ET)
2025-07-24
09:16:13
ImmunoPrecise Antibodies reports LENSai Immunogenicity Screening study results

2025-07-14 (ET)
2025-07-14
08:04:09
ImmunoPrecise Antibodies regains compliance with Nasdaq

2025-07-03 (ET)
2025-07-03
08:32:16
ImmunoPrecise Antibodies announces new validation study on LENSai

Sign Up For More Events
Sign Up For More Events
News
9.0
07-24NewsfilterImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic
5.0
07-21NewsfilterImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board
9.5
07-16NewsfilterIPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025
Sign Up For More News
People Also Watch

CYN
CYNGN Inc
8.890
USD
-5.22%

LSH
Lakeside Holdings Ltd
0.845
USD
+1.68%

SPRB
Spruce Biosciences Inc
0
USD
-64.89%

CVR
Chicago Rivet & Machine Co
12.500
USD
-0.08%

AIRI
Air Industries Group
3.520
USD
+1.73%

RMCF
Rocky Mountain Chocolate Factory Inc (Delaware)
1.840
USD
-1.08%

NCRA
Nocera Inc
1.609
USD
+11.74%

TRIB
Trinity Biotech PLC
0.670
USD
-4.01%

DTSS
Datasea Inc
2.165
USD
+5.10%

XTKG
X3 Holdings Co Ltd
1.800
USD
+2.27%
FAQ

What is Immunoprecise Antibodies Ltd (IPA) stock price today?
The current price of IPA is 2.16 USD — it has decreased -6.49 % in the last trading day.

What is Immunoprecise Antibodies Ltd (IPA)'s business?

What is the price predicton of IPA Stock?

What is Immunoprecise Antibodies Ltd (IPA)'s revenue for the last quarter?

What is Immunoprecise Antibodies Ltd (IPA)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Immunoprecise Antibodies Ltd (IPA)'s fundamentals?

How many employees does Immunoprecise Antibodies Ltd (IPA). have?
